Literature DB >> 32297849

Impact of COVID-19 on traditional healthcare-associated infection prevention efforts.

Michael P Stevens1, Michelle Doll1, Rachel Pryor1, Emily Godbout1, Kaila Cooper1, Gonzalo Bearman1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32297849      PMCID: PMC7188960          DOI: 10.1017/ice.2020.141

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


× No keyword cloud information.
The coronavirus disease 2019 (COVID-19) pandemic has had an enormous impact on healthcare systems globally. Infection prevention resources at the local level, especially in areas of high SARS-CoV-2 activity, have now been diverted to outbreak management. Although these efforts have understandably taken immediate priority, the impacts on traditional healthcare-associated infection (HAI) surveillance and prevention efforts remain concerning. A PubMed search utilizing the search terms “Impact of COVID-19 on healthcare associated infections” was performed on April 5, 2020, and yielded no directly applicable results. An informal Twitter poll was initiated on April 4, 2020, asking the infection prevention and hospital epidemiology community what percentage of their traditional infection prevention time had been diverted to COVID-19 response efforts. This query yielded 220 responses: 79.1% indicated spending >75% of their time on COVID-19 response efforts and another 13.2% indicated spending >50%–75% of their time on these efforts. Although these data are limited, they provide a snapshot of the potential resource diversion affecting the infection prevention community, and these percentages are consistent with our local experience. The potential impacts of the diversion of traditional infection prevention resources to focus on the COVID-19 response are numerous (Fig. 1). With regard to more conventional infection prevention duties, surveillance efforts may be compromised leading to compromised case identification. Process measure data collection may also be compromised (eg, compliance with hand hygiene and chlorhexidine bathing, et cetera). Mitigation efforts are also likely to be affected. In the absence of real-time HAI surveillance and provider and unit feedback, an increase in subsequent HAIs is likely.
Fig. 1.

Potential impact of COVID-19 on healthcare-associated infection prevention efforts.

Potential impact of COVID-19 on healthcare-associated infection prevention efforts. Another concern is the diversion of traditional personal protective equipment (PPE) resources given significant supply-chain shortages. These shortages resulted in the United States Centers for Disease Control and Prevention (CDC) recommending that hospitals experiencing gown shortages stop using isolation gowns for endemic pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and extended-spectrum β-lactamase (ESBL)–producing gram-negative rods. The CDC also noted that gown use could be suspended in nonendemic settings for lower-risk patient encounters.[1] Such strategies may lead, especially if the local healthcare personnel infrastructure is also compromised, to more cross transmission and HAIs. The impacts on antimicrobial stewardship programs (ASPs), many of which are integrated with infection prevention programs, may also be significant.[2] ASP efforts may be diverted to assist with COVID-19 response efforts, with a negative subsequent impact on activities such as post-antibiotic order review with provider feedback. An influx of critically ill patients may drive suboptimal antibiotic use with subsequent concern for the development of antibiotic resistance and C. difficile infection as well. Another major concern is the potential impact of increased HAI rates on health systems in terms of public reporting and quality programs associated with reimbursement. Predictably, health systems will be negatively impacted by the global pandemic, and further penalties related to an increase in HAIs will further stress these systems. Although these measures are well-intentioned, consideration for relaxing penalties during the pandemic (and for a period afterward) should be considered. The Centers for Medicare and Medicaid Services (CMS) penalized ~800 hospitals for their HAI performance between October 2018 and September 2019, resulting in a 1% loss of reimbursement for Medicare patients.[3] Fortunately, the CMS announced that reporting to the hospital-acquired condition (HAC) program is optional for the fourth quarter of 2019. Furthermore, data for the first 2 quarters of 2020 will not be counted for performance or repayment, and the related data do not need to be submitted to the CMS.[4] Other non-CMS quality programs that utilize publicly reported HAI data to determine penalties should also consider adopting similar nonpenalty measures in the face of the current global health crisis. Health systems should consider creative ways to support and bolster their infection prevention programs during the COVID-19 pandemic. These efforts should include investment in information technology and personnel. Although health systems may be willing to invest resources and money in these programs, few trained infection preventionists and hospital epidemiologists are available in the United States. Beyond the current pandemic, significant resources should be invested to improve and sustain infection prevention infrastructure at the local, regional and national levels. Additionally, new investment in training and expanding the infection prevention workforce will be critical. The full impact of the COVID-19 pandemic on health systems and traditional HAIs remains to be determined. Significant infection prevention resource diversion is occurring to help manage the outbreak at the health-system level, which will predictably impact HAI surveillance and prevention efforts. The CMS has recognized the challenges facing the infection prevention community and have suspended penalties associated with the HAC program temporarily. Other quality programs should consider similar measures. Now more than ever, health systems should continue investing in their infection prevention programs (both infrastructure and personnel) beyond the current pandemic.
  1 in total

1.  Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck.

Authors:  Michael P Stevens; Payal K Patel; Priya Nori
Journal:  Infect Control Hosp Epidemiol       Date:  2020-06       Impact factor: 6.520

  1 in total
  12 in total

1.  An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs.

Authors:  Nour Shbaklo; Silvia Corcione; Costanza Vicentini; Susanna Giordano; Denise Fiorentino; Gabriele Bianco; Francesco Cattel; Rossana Cavallo; Carla Maria Zotti; Francesco Giuseppe De Rosa
Journal:  Antibiotics (Basel)       Date:  2022-05-20

2.  Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?

Authors:  Dominique L Monnet; Stephan Harbarth
Journal:  Euro Surveill       Date:  2020-11

3.  Impact of COVID-19 on Traditional Healthcare Associated Infection Prevention Efforts - CORRIGENDUM.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  2020-05-29       Impact factor: 3.254

4.  Trends of Healthcare-associated Infections in a Tuinisian University Hospital and Impact of COVID-19 Pandemic.

Authors:  Hela Ghali; Asma Ben Cheikh; Sana Bhiri; Selwa Khefacha; Houyem Said Latiri; Mohamed Ben Rejeb
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

5.  Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?

Authors:  Andre C Kalil; Kelly A Cawcutt
Journal:  Crit Care Med       Date:  2022-03-01       Impact factor: 9.296

6.  Comparing the Occurrence of Healthcare-Associated Infections in Patients with and without COVID-19 Hospitalized during the Pandemic: A 16-Month Retrospective Cohort Study in a Hospital Intensive Care Unit.

Authors:  Claudia Isonne; Valentina Baccolini; Giuseppe Migliara; Mariateresa Ceparano; Francesco Alessandri; Giancarlo Ceccarelli; Guglielmo Tellan; Francesco Pugliese; Maria De Giusti; Corrado De Vito; Carolina Marzuillo; Paolo Villari; Lavinia Camilla Barone; Dara Giannini; Daniela Marotta; Mattia Marte; Elena Mazzalai; Irma Germani; Arianna Bellini; Andrea Bongiovanni; Marta Castellani; Ludovica D'Agostino; Andrea De Giorgi; Chiara De Marchi; Elisa Mazzeo; Shadi Orlandi; Matteo Piattoli; Eleonora Ricci; Leonardo Maria Siena; Alessandro Territo; Stefano Zanni
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

7.  Healthcare-associated infections on the ICU in 21 Brazilian hospitals during the early months of the COVID-19 pandemic: an ecological study.

Authors:  Ana Paula M Porto; Igor C Borges; Lewis Buss; Anna Machado; Bil R Bassetti; Brunno Cocentino; Camila S Bicalho; Claudia Carrilho; Cristhieni Rodrigues; Eudes A S Neto; Evelyne S Girão; Filipe Piastrelli; Giovanna Sapienza; Glaucia Varkulja; Karin Kolbe; Luciana Passos; Patricia Esteves; Pollyana Gitirana; Regia D F Feijó; Rosane L Coutinho; Thais Guimarães; Tiago L L Ferraz; Anna S Levin; Silvia F Costa
Journal:  Infect Control Hosp Epidemiol       Date:  2022-03-18       Impact factor: 3.254

8.  The impact of COVID-19 pandemic on hand hygiene performance in hospitals.

Authors:  Lori D Moore; Greg Robbins; Jeff Quinn; James W Arbogast
Journal:  Am J Infect Control       Date:  2020-08-18       Impact factor: 2.918

9.  Impact of a total lockdown for pandemic SARS-CoV-2 (Covid-19) on deep surgical site infections and other complications after orthopedic surgery: a retrospective analysis.

Authors:  Ines Unterfrauner; Laura A Hruby; Peter Jans; Ludwig Steinwender; Mazda Farshad; Ilker Uçkay
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-31       Impact factor: 4.887

Review 10.  Changing Epidemiology of Respiratory Tract Infection during COVID-19 Pandemic.

Authors:  Hung-Jen Tang; Chih-Cheng Lai; Chien-Ming Chao
Journal:  Antibiotics (Basel)       Date:  2022-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.